A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma (TRI Pro)
Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to find out whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome (CRS) within 28 days from ramantamig, compared to participants who receive placebo. CRS is an acute inflammatory reaction that can occur during treatment and may be associated with flu-like or other systemic symptoms, such as fever and tiredness.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Study Contact
- 電話番号:844-434-4210
- メール:Participate-In-This-Study1@its.jnj.com
研究場所
-
-
Arizona
-
Goodyear、Arizona、アメリカ、85338
- 募集
- City of Hope Phoenix
-
-
California
-
Beverly Hills、California、アメリカ、90211
- 募集
- Beverly Hills Cancer Center (BHCC)
-
Irvine、California、アメリカ、92618
- 募集
- City of Hope Orange County Lennar Foundation Cancer Center
-
Palo Alto、California、アメリカ、94304
- 募集
- Stanford University Medical Center
-
-
Colorado
-
Denver、Colorado、アメリカ、80218
- 募集
- Colorado Blood Cancer Institute
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110
- 募集
- Washington University School Of Medicine
-
-
Ohio
-
Columbus、Ohio、アメリカ、43214
- 募集
- Ohio Health Research Institute
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37203
- 募集
- Sarah Cannon Research Institute
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112
- 募集
- University of Utah Huntsman Cancer Institute
-
-
-
-
-
Buenos Aires、アルゼンチン、C1199ABB
- 募集
- Hospital Italiano de Buenos Aires
-
Buenos Aires、アルゼンチン、C1426ANZ
- 募集
- Instituto Alexander Fleming
-
Buenos Aires、アルゼンチン、C1118
- 募集
- Hospital Aleman
-
Córdoba、アルゼンチン、X5016KEH
- 募集
- Hospital Privado Centro Medico de Cordoba
-
Pilar、アルゼンチン、1629
- 募集
- Hospital Universitario Austral
-
-
-
-
-
Bedford Park、オーストラリア、5042
- 募集
- Flinders Medical Centre
-
Birtinya、オーストラリア、4575
- 募集
- Sunshine Coast University Hospital
-
Concord、オーストラリア、2139
- 募集
- Concord Repatriation General Hospital
-
Fitzroy、オーストラリア、3065
- 募集
- St Vincents Hospital Melbourne
-
Wollongong、オーストラリア、2500
- 募集
- Wollongong Hospital
-
-
-
-
-
Alexandroupoli、ギリシャ、681 00
- 募集
- Uni General Hospital of Alexandroupolis
-
Athens、ギリシャ、11528
- 募集
- Alexandra General Hospital of Athens
-
Athens、ギリシャ、115 25
- 募集
- 251 Air Force General Hospital
-
Piraeus、ギリシャ、18537
- 募集
- Metaxa Cancer Center Hospital Of Piraeus
-
Rio、ギリシャ、265 04
- 募集
- General University Hospital of Patras
-
Thessaloniki、ギリシャ、54642
- 募集
- Hippokration Hospital
-
Thessaloniki、ギリシャ、546 39
- 募集
- Theageneio Cancer Hospital
-
-
-
-
-
Falun、スウェーデン、791 82
- 募集
- Falu Lasarett Medicinkliniken Falun
-
Gothenburg、スウェーデン、413 45
- 募集
- Sahlgrenska Universitetssjukhuset
-
Lund、スウェーデン、221 85
- 募集
- Skanes universitetssjukhus
-
Stockholm、スウェーデン、141 86
- 募集
- Karolinska University Hospital Huddinge
-
Uppsala、スウェーデン、752 37
- 募集
- Akademiska Sjukhuset
-
-
-
-
-
Barcelona、スペイン、08041
- 募集
- Hosp. de La Santa Creu I Sant Pau
-
León、スペイン、24071
- 募集
- Hosp. de Leon
-
Madrid、スペイン、28046
- 募集
- Hosp. Univ. La Paz
-
Madrid、スペイン、28055
- 募集
- Hosp. Blua Sanitas Valdebebas
-
Málaga、スペイン、29010
- 募集
- Hosp Regional Univ de Malaga
-
Pamplona、スペイン、31008
- 募集
- Hosp. de Navarra
-
Valencia、スペイン、46017
- 募集
- Hosp. Univ. Dr. Peset
-
-
-
-
-
Budapest、ハンガリー、1088
- 募集
- Semmelweis Egyetem
-
Budapest、ハンガリー、1097
- 募集
- Del Pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet Szent Laszlo Telephely
-
Budapest、ハンガリー、1122
- 募集
- Orszagos Onkologiai Intezet
-
Pécs、ハンガリー、7624
- 募集
- Pecsi Tudomanyegyetem Klinikai Kozpont
-
Szeged、ハンガリー、6725
- 募集
- Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar
-
-
-
-
-
Argenteuil、フランス、95107
- 募集
- Centre Hospitalier Victor Dupouy
-
Bayonne、フランス、64100
- 募集
- Centre Hospitalier de la Cote Basque
-
La Tronche、フランス、38700
- 募集
- CHU de Grenoble
-
Le Mans、フランス、72100
- 募集
- Centre de Cancerologie de la Sarthe
-
Nantes、フランス、44000
- 募集
- CHU Nantes - Hotel Dieu
-
Quimper、フランス、29000
- 募集
- Centre Hospitalier de Quimper Cornouaille
-
-
-
-
-
Braga、ポルトガル、4710 243
- 募集
- Uls Braga - Hosp. Braga
-
Lisbon、ポルトガル、1099 023
- 募集
- Ipo Lisboa
-
Lisbon、ポルトガル、1998 018
- 募集
- Hosp. Cuf Descobertas
-
Porto、ポルトガル、4200 319
- 募集
- Uls Sao Joao - Hosp. Sao Joao
-
Porto、ポルトガル、4050 342
- 募集
- Uls Santo Antonio - Hosp. Santo Antonio
-
Vila Nova de Gaia、ポルトガル、4434 502
- 募集
- Uls Gaia Espinho
-
-
-
-
-
Ampang、マレーシア、68000
- 募集
- Hospital Ampang
-
George Town、マレーシア、10450
- 募集
- Hospital Pulau Pinang
-
Johor Bharu、マレーシア、80100
- 募集
- Hospital Sultanah Aminah
-
Kota Kinabalu、マレーシア、88586
- 募集
- Hospital Queen Elizabeth
-
Kuching、マレーシア、93586
- 募集
- Sarawak General Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion criteria:
- Documented diagnosis of multiple myeloma (MM) as defined by the criteria: a. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria; b. Measurable disease at screening as assessed by local laboratory as defined in the protocol
- Received at least 1 prior lines of antimyeloma therapy
- Relapsed or refractory disease as defined: a. Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease (PD) by the IMWG response criteria greater than (>) 60 days after cessation of treatment.; b. Refractory disease is defined as failure to achieve a response or confirmed PD by the IMWG response criteria during previous treatment or less than or equal to (<=) 60 days after cessation of treatment
- Have an eastern cooperative oncology group (ECOG) performance status (PS) score of 0 to 2 at screening and immediately before the start of study treatment administration. Participants with ECOG PS 2 or 3 are eligible for the study if the ECOG PS score is related to stable physical limitations (example, wheelchair-bound due to prior spinal cord injury) and not related to MM or associated therapy
- Have clinical laboratory values meeting the criteria specified in the protocol
Exclusion criteria:
- Concurrent use of any other anticancer treatment (including non-palliative radiotherapy) or investigational agent
- Major surgery, (for example, requiring general anesthesia) within 2 weeks before first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study
- Suspected or known allergies, hypersensitivity, or intolerance to ramantamig and tocilizumab or their excipients
- Presence of any of the following: a. Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM); b. Any history of malignancy, other than MM, that is considered at high risk of recurrence requiring systemic therapy; c. Any active malignancy other than MM
- Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm A: Tocilizumab + Ramantamig
Participants will receive tocilizumab along with ramantamig. Ramantamig will be administered for a total treatment of finite duration, or until progressive disease (PD) or intolerable toxicity (whichever is earlier). |
Ramantamig will be administered as subcutaneous (SC) injection.
他の名前:
Tocilizumab will be administered as intravenous (IV) injection. |
|
プラセボコンパレーター:Arm B: Placebo + Ramantamig
Participants will receive placebo (saline) along with ramantamig. Ramantamig will be administered for a total treatment of finite duration, or until PD or intolerable toxicity (whichever is earlier). |
Ramantamig will be administered as subcutaneous (SC) injection.
他の名前:
Placebo (saline) will be administered as IV injection. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants Alive and Free of Treatment-Emergent American Society for Transplantation and Cellular Therapy (ASTCT) Grade Greater Than or Equal to (>=) 2 Cytokine Release Syndrome (CRS)
時間枠:By the end of Day 28 from first ramantamig dose
|
Percentage of participants alive and free of treatment-emergent ASTCT Grade >=2 CRS without the use of intervening treatment for CRS of any grade by the end of day 28 from first ramantamig dose will be reported. |
By the end of Day 28 from first ramantamig dose
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants with Treatment-Emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 by the End of Day 28 from First Ramantamig Dose
時間枠:By the end of Day 28 from first ramantamig dose
|
Percentage of participants with treatment-emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 by the end of day 28 from first ramantamig dose, respectively, will be reported. |
By the end of Day 28 from first ramantamig dose
|
|
Percentage of Participants with Treatment-Emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 During Ramantamig Treatment
時間枠:Up to 38 months
|
Percentage of participants with treatment-emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 during ramantamig treatment will be reported. |
Up to 38 months
|
|
Percentage of Participants with Re-occurrence of CRS with ASTCT Grade >=2 After the Initial Occurrence of Treatment-Emergent Grade >=2 CRS Event
時間枠:Up to 38 months
|
Percentage of participants with re-occurrence of CRS with ASTCT Grade >=2 after the initial occurrence of treatment-emergent Grade >=2 CRS event will be reported. |
Up to 38 months
|
|
Percentage of Participants with Re-occurrence of CRS for All Grades
時間枠:Up to 38 months
|
Percentage of participants with re-occurrence of CRS for all Grades will be reported. |
Up to 38 months
|
|
Overall Response
時間枠:Up to 38 months
|
Overall response is defined as the percentage of participants who achieve partial response (PR) or better prior to progressive disease (PD) or subsequent antimyeloma therapy, in accordance with the international myeloma working group (IMWG) criteria. |
Up to 38 months
|
|
Complete Response (CR) or Better
時間枠:Up to 38 months
|
CR or better rate is defined as the percentage of participants achieving CR or stringent complete response (sCR) prior to PD or subsequent antimyeloma therapy, in accordance with the IMWG criteria. |
Up to 38 months
|
|
Very Good Partial Response (VGPR) or Better
時間枠:Up to Month 38
|
VGPR or better rate is defined as the percentage of participants achieving VGPR, CR or sCR prior to PD or subsequent antimyeloma therapy, in accordance with the IMWG criteria. |
Up to Month 38
|
|
Duration of Response (DoR)
時間枠:Up to 38 months
|
DoR is defined as the time interval between the date of initial documentation of a response (PR or better) to the date of first documented evidence of PD according to the IMWG response criteria or death due to any cause, whichever occurs first. |
Up to 38 months
|
|
Time to Response (TTR)
時間枠:Up to 38 months
|
TTR is defined as the time from the date of randomization to the date of first documentation of a confirmed response (PR or better) for participants who have PR or better as their best response. |
Up to 38 months
|
|
Progression-Free Survival (PFS)
時間枠:Up to Month 38
|
PFS is defined as the duration from the date of randomization to either PD or death, whichever comes first. Disease progression will be determined according to the IMWG response criteria. |
Up to Month 38
|
|
Time to Subsequent Antimyeloma Therapy
時間枠:Up to Month 38
|
Time to subsequent antimyeloma therapy is defined as the time from randomization to the start of subsequent antimyeloma treatment. Death due to progressive disease without the start of any subsequent antimyeloma therapy will be considered as an event. |
Up to Month 38
|
|
Percentage of Participants With Treatment-Emergent Adverse Event (TEAE) by Severity
時間枠:Up to 38 months
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. Any new or worsening AE occurring at or after the initial administration of study treatment through the day of last dose plus 30 days or prior to the start of subsequent antimyeloma therapy, whichever is earlier, or any follow-up AE (linked to an existing TEAE) with onset date and time beyond 30 days after the last dose of study treatment but prior to the start of subsequent therapy, or any AE that is considered treatment-related regardless of the start date of the event, is considered to be treatment-emergent. TEAEs will be graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 6.0. Severity scale ranges from Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, Grade 5= death related to adverse event. |
Up to 38 months
|
|
Percentage of Participants with Abnormalities in Laboratory Parameters
時間枠:Up to 38 months
|
Percentage of participants with abnormalities in laboratory parameters (serum chemistry and hematology) will be reported. |
Up to 38 months
|
|
Percentage of Participants with Incidence of Adverse Events of Clinical Interests
時間枠:Up to 38 Months
|
Percentage of participants with incidence of adverse events of clinical interests such as cytopenia will be reported. |
Up to 38 Months
|
協力者と研究者
捜査官
- スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 79635322MMY2002
- 2025-524793-42 (EudraCT番号)
- 2025 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。